Authors

Latest:

Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCC

Michael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.

Eric Vail, MD

Latest:

Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung Cancer

Eric Vail, MD, discusses emerging advances in biomarker testing in lung cancer.

Harsh Parmar, MD

Latest:

Recommendations For Future Clinical Trials in R/R MM

Panelists discuss how insights from ASH 2024 highlight the need for personalized treatment strategies, improved trial designs, and greater inclusion of diverse patient populations in future clinical trials for relapsed/refractory multiple myeloma (R/R MM).

Amod Sarnaik, MD

Latest:

TIL Therapy: Lessons Learned and Potential Future Directions in Care

Experts Amod Sarnaik, MD, and Krishna Komanduri, MD, consider lessons learned about TILs and CAR T-cell therapy in hematologic cancers, and how they anticipate TILs fitting into treatment paradigms for solid tumors.

Meghan J. Mooradian, MD

Latest:

Emerging Concepts on the Role of Immunotherapy in NSCLC

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Nishanth Thalambedu, MD

Latest:

Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology Fellow

Tumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.

Priya K Bhatt, APRN

Latest:

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Jeff Bendix

Latest:

Reducing Burnout Requires an Organizational Response

A new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.

Andrea L. Silber, MD

Latest:

Dr. Silber on the Importance of Improving Clinical Trial Inclusivity in Breast Cancer

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Amer M. Beitinjaneh, MD

Latest:

Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic Malignancies

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Myriam Chalabi, MD

Latest:

Dr. Chalabi on the Role of MSI Testing in CRC

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Girindra Raval, MD

Girindra Raval, MD, is an associate professor in the Department of Medicine: Hematology and Oncology at the Medical College of Georgia of Augusta University.

Latest:

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Travis J. Osterman, DO

Latest:

How to Make Clinical Decisions With AI in Oncology

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Chih-Yi Liao, MD

Latest:

Dr Liao on the Value of Molecular Testing in Biliary Tract Carcinoma

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Jonathan Coggins, MHA

Latest:

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

Patricia Pautier, MD

Latest:

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.

Benjamin Levy, MD

Latest:

Patient Selection and Sequencing of NSCLC ADCs

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Timothy J. Pluard, MD

Latest:

Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Michael Cecchini, MD

Michael Cecchini, MD, is an associate professor of medicine (medical oncology) at Yale School of Medicine; as well as the co-director of the Colorectal Program in the Center for Gastrointestinal (GI) Cancers, the medical oncology section lead for the National Accreditation Program for Rectal Cancer, the co-director of the GI Clinical Research Team, and a phase 1 investigator at Yale Cancer Center

Latest:

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.